Skip to main content

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Recruiting · Phase 2, Phase 3 · NCT04613596

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

At a glance

Research payments reported, 2025
$2.0M
U.S. investigators named
57
Sites paid
32
Planned or actual enrollment
626

About the trial

Sponsor
Mirati Therapeutics Inc.
Tested
Adagrasib (drug), Adagrasib (drug), Adagrasib (drug), Adagrasib (drug), Pembrolizumab (drug)
Dates
Started 2020-12-02; completion 2029-10-31
Results posted
Not yet

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Mirati Therapeutics, Inc. reported $2.0M in research payments for this study in 2025 (57 payments).

Products named: Krazati

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Us Oncology Res Llc $950,538
  • Sarah Cannon Research Institute, Llc $184,217
  • Memorialcare Health System $170,654
  • Exigent Research Llc $111,248
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $84,962
  • Biomedical Research Alliance of New York, Llc $66,210
  • Baptist Health Lexington, KY $58,962
  • West Clinic $57,378
  • Highlands Oncology Group $31,580
  • Northwest Georgia Oncology Centers, PC $31,480
  • Veterans Research Foundation of Pittsburgh $31,410
  • Medstar Research Institute $30,500
  • The University of Chicago Kovler Diabetes Center $28,036
  • American Oncology PArtners $22,630
  • Cancer Center of Kansas $21,185
  • Jackson Oncology Associates, PLLC $16,142
  • Dana-Farber Cancer Institute $15,706
  • Duke University $15,327
  • University of Louisville Research Foundation, Inc, $15,211
  • South Florida VA Foundation for Research and Education, Inc $13,910
  • Tampa VA Research and Education Foundation Inc $13,866
  • Northern California Institute for Research and Education $9,337
  • Mayo Clinic Jacksonville $9,036
  • Johns Hopkins University School of Medicine $5,632
  • Hackensack University Medical Center, NJ $5,069
  • Care Access Research Llc $4,850
  • Bay Pines VA Health Care System $4,000
  • Cancer and Blood Specialty Clinic $3,481
  • Advocate Christ Hospital & Medical Center, IL $3,352
  • Oneoncology $3,114
  • New York Oncology Hematology, PC $1,074
  • Adventhealth Orlando, FL $600

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.